Nguyen, Bastien
Sanchez-Vega, Francisco
Fong, Christopher J.
Chatila, Walid K.
Boroujeni, Amir Momeni
Pareja, Fresia
Weigelt, Britta
Sotiriou, Christos
Larsimont, Denis
Reis-Filho, Jorge S.
Desmedt, Christine
Schultz, Nikolaus
Funding for this research was provided by:
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, a National Cancer Institute Cancer Center Core Grant (P30-CA008748)
Breast Cancer Research Foundation
Congressionally Directed Medical Research Programs
Thompson Family Foundation
Robertson Foundation
Article History
Received: 25 February 2020
Accepted: 19 March 2021
First Online: 4 May 2021
Competing interests
: B.N., F.S.V., W.K.C., A.M.B., F.P., C.D., B.W., N.S., C.F., D.L.: no disclosures. J.S.R.-F. reports receiving personal/consultancy fees from VolitionRx, Paige.AI, Goldman Sachs, REPARE Therapeutics, GRAIL, Ventana Medical Systems, Roche, Genentech and InVicro outside of the scope of the submitted work. C.S. has patents on gene expression and methylation signatures. He has served on advisory boards, and/or speaker at meetings, and/or recipient of travel support for participation in medical meetings for/from (in alphabetical order) from Amgen, Astellas, AstraZeneca, Bayer, Celgene, Nanostring Technologies, Novartis, Pfizer, Roche.